Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457605 | 1.00 | KDM1A (0.55) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL29457639 | 1.00 | KDM1A (0.55) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL6648372 | 0.87 | KDM1A (0.54) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL7004085 | 0.87 | KDM1A (0.50) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL24867123 | 0.86 | KDM1A (0.53) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL1985926 | 0.86 | KDM1A (0.59) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL26090253 | 0.86 | KDM1A (0.59) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL30346003 | 0.86 | KDM1A (0.59) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL5561495 | 0.86 | KDM1A (0.53) | KDM1AHDAC1HDAC6GPR119BCHE | |
| SCHEMBL31357047 | 0.82 | KDM1A (0.49) | KDM1AHDAC1HDAC6GPR119BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-1964925-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-7972836-B2 | Method of enzymatic optical resolution of racemic 4-hydroxy-1,2,3,4-tetrahydroquinoline | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090269821-A1 | Method for Preparing Optically Active 4-Hydroxy-1,2,3,4-Tetrahydroquinoline Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1964925-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-03 | — | — | EP | disclosed |
| EP-1408970-B1 | INDOLINES AND TETRAHYDRO-QUINOLINES AS PRODRUGS FOR TUMOUR TREATMENT | UNIV LONDON PHARMACY (GB) | 2007-05-09 | — | — | EP | disclosed |
| US-7179921-B2 | Indoline and tetrahydro-quinolines as prodrugs for tumour treatment | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2007-02-20 | — | — | US | disclosed |
| US-20040157880-A1 | Indoline and tetrahydro-quinolines as prodrugs for tumour treatment | UNIVERSITY OF BRADFORD (GB) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | KDM1A 2120/4885HDAC1 2076/4885HDAC6 1177/4885 |
| US-20040157880-A1 | Indoline and tetrahydro-quinolines as prodrugs for tumour treatment | CYP1B1, TOP1, UGT1A1 | KDM1A 458/4885HDAC1 245/4885HDAC6 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.